-
January 28, 2010 Lupin Strengthens its Board; Appoints Three Independent Directors
-
January 28, 2010 Lupin receives US FDA approval for Perindopril Erbumine Tablets
-
January 20, 2010 Lupin receives US FDA tentative approval for Memantine HCl tablets
-
December 22, 2009 Lupin Announces Litigation Settlement with Forest for Memantine Tablets
-
October 5, 2009 Lupin licenses us rights for proprietary bioadhesive technology for rifaximin to salix pharmaceuticals
-
September 25, 2009 Lupin Expands Branded Play Announces Acquisition of US Rights to ANTARA
-
September 18, 2009 Lupin ties up with leading Institutes for PhD Program
-
July 29, 2009 Lupin Net Profit up by 25 % in Q1, FY 2009-10 Outpacing and Outperforming Markets globally
-
June 30, 2009 Lupin Expands Branded Play Announces Acquisition of Worldwide Rights for its first NDA – AllerNaze™
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications